Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$12.24 – $13.26
Volume14,122
Market cap$52M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$52.11M
Price / earnings
—
Price / book
-2.31×
Price / sales
—
EV / sales
—
EV / EBITDA
-4.32×
Profitability
Earnings per share
-$3.47
Return on assets
-827.28%
Return on equity
62.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.17×
Current ratio
0.07×
Quick ratio
0.07×
Cash ratio
0.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
—
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELOX, quarterly periods
Line item
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2023 Dec 31, 2023
Q3 FY2023 Sep 30, 2023
Q2 FY2023 Jun 30, 2023
Q1 FY2023 Mar 31, 2023
Revenue
$0
$0
$0
$0
—
$0
—
—
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
—
$0
—
—
Selling, general and administrative
$1.61M
$2.14M
$684K
$712K
—
$2.39M
$1.8M
$2M
Research and development
$2.84M
$1.66M
$898K
$510K
—
$1.25M
$2.34M
$3.49M
Total operating expenses
$4.45M
$3.8M
$1.58M
$1.22M
—
$3.64M
$4.14M
$5.48M
Operating income
-$4.45M
-$3.8M
-$1.58M
-$1.22M
—
-$3.64M
-$4.14M
-$5.48M
Interest expense
$0
$0
$0
$0
—
$0
—
—
Income before taxes
-$4.5M
-$3.75M
-$1.89M
-$1.71M
—
-$3.59M
-$4.34M
-$6.23M
Income taxes
$0
$0
$0
$0
—
$0
—
—
Net income
-$4.5M
-$3.75M
-$1.89M
-$1.71M
—
-$3.59M
-$4.34M
-$6.23M
Net income attributable to common shareholders
-$4.5M
-$3.75M
-$1.89M
-$1.71M
—
-$3.59M
-$4.34M
-$6.23M
EBITDA
-$4.45M
-$3.8M
-$1.58M
-$1.22M
$0
-$3.45M
-$3.96M
-$5.3M
Basic earnings per share
-$0.66
-$0.08
-$5.45
-$0.45
—
-$1.31
-$1.96
-$2.88
Diluted earnings per share
-$0.66
-$0.08
-$5.45
-$0.45
—
-$1.31
-$1.96
-$2.88
Recent news
Company coverage with links to the original publishers.
The global mucopolysaccharidosis treatment market is expected to grow significantly, driven by advancements in biotechnology, improved diagnostic techniques, and increased awareness of rare diseases. The market is projected to reach $5,014.5 million by 2035, growing at a CAGR of 5.9%.
The article discusses the prevalence and impact of rare genetic disorders, which affect over 350 million people worldwide. It highlights the challenges in treating these conditions, including limited treatment options and underfunding for research. The article also provides an overview of the market analysis for various rare genetic disorders, including Usher Syndrome, Alport Syndrome, Menkes Disease, and others.
Eloxx Pharmaceuticals, a biopharmaceutical company, has secured an additional $3.175 million in funding through a loan agreement amendment with Hercules Capital and other lenders. The funding will be used for the company's operations and development of its ELX-02 compound.
Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.